At a glance
- Originator The Institute of Cancer Research
- Class Antineoplastics; Dipeptides
- Mechanism of Action Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 08 Jul 1998 No-Development-Reported for Cancer in United Kingdom (Unknown route)
- 01 May 1995 Preclinical development for Cancer in United Kingdom (Unknown route)